PIK3CA and breast carcinoma: An ongoing phase II study, entitled “Alpelisib, Fulvestrant and Dapagliflozin (SGLT2 inhibitor) for the Treatment of ER-positive, HER2-negative, PIK3CA-Mutant Metastatic Breast Cancer”, includes the same population as the SOLAR-1 trial to establish if the addition of dapagliflozin, an SGLT-2 inhibitor, could significantly reduce hyperglycemia of any grade (NCT05025735).